Literature DB >> 24927731

Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure.

Ewa A Jankowska1, Monika Kasztura2, Mateusz Sokolski3, Marek Bronisz4, Sylwia Nawrocka5, Weronika Oleśkowska-Florek4, Robert Zymliński5, Jan Biegus5, Paweł Siwołowski5, Waldemar Banasiak5, Stefan D Anker6, Gerasimos Filippatos7, John G F Cleland8, Piotr Ponikowski3.   

Abstract

AIM: Acute heart failure (AHF) critically deranges haemodynamic and metabolic homoeostasis. Iron is a key micronutrient for homoeostasis maintenance. We hypothesized that iron deficiency (ID) defined as depleted iron stores accompanied by unmet cellular iron requirements would in this setting predict the poor outcome. METHODS AND
RESULTS: Among 165 AHF patients (age 65 ± 12 years, 81% men, 31% de novo HF), for ID diagnosis we prospectively applied: low serum hepcidin reflecting depleted iron stores (<14.5 ng/mL, the 5th percentile in healthy peers), and high-serum soluble transferrin receptor (sTfR) reflecting unmet cellular iron requirements (≥1.59 mg/L, the 95th percentile in healthy peers). Concomitance of low hepcidin and high sTfR (the most profound ID) was found in 37%, isolated either high sTfR or low hepcidin was found in 29 and 9% of patients, and 25% of subjects demonstrated preserved iron status. Patients with low hepcidin and high sTfR had peripheral oedema, high NT-proBNP, high uric acid, low haemoglobin (P < 0.05), and 5% in-hospital mortality (0% in remaining patients). During the 12-month follow-up, 33 (20%) patients died. Those with low hepcidin and high sTfR had the highest 12-month mortality [(41% (95% CI: 29-53%)] when compared with those with isolated high sTfR [15% (5-25%)], isolated low hepcidin [7% (0-19%)] and preserved iron status (0%) (P < 0.001). Analogous mortality patterns were seen separately in anaemics and non-anaemics.
CONCLUSION: Iron deficiency defined as depleted body iron stores and unmet cellular iron requirements is common in AHF, and identifies those with the poor outcome. Its correction may be an attractive therapeutic approach. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Acute heart failure; Hepcidin; Iron status; Mortality; Soluble transferrin receptor

Mesh:

Substances:

Year:  2014        PMID: 24927731     DOI: 10.1093/eurheartj/ehu235

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  54 in total

Review 1.  Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials.

Authors:  Kunal N Bhatt; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2018-06

2.  Deregulated iron metabolism in bone marrow from adenine-induced mouse model of chronic kidney disease.

Authors:  Tomoko Kimura; Takahiro Kuragano; Kiyoko Yamamoto; Masayoshi Nanami; Yukiko Hasuike; Takeshi Nakanishi
Journal:  Int J Hematol       Date:  2018-09-19       Impact factor: 2.490

Review 3.  Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?

Authors:  Lucas N L Van Aelst; Dominiek Mazure; Alain Cohen-Solal
Journal:  Curr Heart Fail Rep       Date:  2017-08

4.  Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting.

Authors:  Giacomo Marchi; Fabiana Busti; Alice Vianello; Domenico Girelli
Journal:  Intern Emerg Med       Date:  2020-07-10       Impact factor: 3.397

Review 5.  [Acute and chronic heart failure].

Authors:  K-P Kresoja; G Schmidt; B Kherad; F Krackhardt; F Spillmann; C Tschöpe
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

Review 6.  Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.

Authors:  Werner Budts; Jolien Roos-Hesselink; Tanja Rädle-Hurst; Andreas Eicken; Theresa A McDonagh; Ekaterini Lambrinou; Maria G Crespo-Leiro; Fiona Walker; Alexandra A Frogoudaki
Journal:  Eur Heart J       Date:  2016-01-18       Impact factor: 29.983

7.  Screening for Biomarkers Associated with Left Ventricular Function During Follow-up After Acute Coronary Syndrome.

Authors:  Christina Christersson; Tomasz Baron; Frank Flachskampf; Lars Lindhagen; Bertil Lindahl; Agneta Siegbahn
Journal:  J Cardiovasc Transl Res       Date:  2022-06-21       Impact factor: 4.132

8.  Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure.

Authors:  Gregory D Lewis; Marc J Semigran; Michael M Givertz; Rajeev Malhotra; Kevin J Anstrom; Adrian F Hernandez; Monica R Shah; Eugene Braunwald
Journal:  Circ Heart Fail       Date:  2016-05       Impact factor: 8.790

Review 9.  Iron Therapy in Heart Failure: Ready for Primetime?

Authors:  Ify R Mordi; Aaron Tee; Chim C Lang
Journal:  Card Fail Rev       Date:  2018-05

Review 10.  Role of iron homeostasis in the heart : Heart failure, cardiomyopathy, and ischemia-reperfusion injury.

Authors:  Hangying Ying; Zhida Shen; Jiacheng Wang; Binquan Zhou
Journal:  Herz       Date:  2021-05-12       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.